TissueScan, Breast Cancer cDNA Array IV

SKU
BCRT104
48 samples covering 4-normal, 2-Stage I, 15-IIA, 9-IIB, 7-IIIA, 4-IIIB, 6-IIIC, 1-IV. Available in 2, 5, 10 identical plates.
New! ER, PR and HER2 in Clinical Info.
  $1,060.00
In Stock*
Specifications
Specifications
Product Data
TissueScan Type Cancer Specific
Array Name Breast Cancer cDNA Array IV
Clinical Info
Diagnosis Category Breast Cancer
Tissue Breast
Shipping Ambient
Description 48 samples covering 4-normal, 2-Stage I, 15-IIA, 9-IIB, 7-IIIA, 4-IIIB, 6-IIIC, 1-IV. Available in 2, 5, 10 identical plates.
New! ER, PR and HER2 in Clinical Info.
Reviews
 
 
 
 
 

Be the first to review this product

Please note:
Only reviews with images are eligible for a $20/20€ Amazon gift card.
Reviews without images are eligible for a $10/10€ Amazon gift card.
For more details about the terms and conditions, please visit the promotion page.

Review image
Documents
Resources

file-alt Citations

Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide
Jannoo, Walker, Kanamarlapudi
Cancers (2023) 15 (10), 2772 DOI: 10.3390/cancers15102772
Cited by 7
AI Summary: OriGene’s TissueScan™ Breast Cancer cDNA Arrays (CSRT104, BCRT103, and BCRT104) were used in this study to assess IL-13Rα2 mRNA expression across various stages of breast cancer and non-malignant tissues, enabling the evaluation of IL-13Rα2 as a therapeutic target.
Snippet: …For example, IL-13 conjugated with Pseudomonas exotoxin subunits (IL-13;To determine relative IL-13Rα2 mRNA expression in breast cancer tumors representing various stages of the disease, a similar RT-PCR methodology was applied to Origene TissueScan Breast Cancer cDNA Arrays (samples from CSRT104, BCRT103, and BCRT104;60 tumor samples (n = 60) covering various disease stages with non-malignant (n = 7) breast tissue cDNA samples for comparison) [37]
Identification of an mRNA isoform switch for HNRNPA1 in breast cancers
Erdem, Ozgul, Dioken et al
Sci Rep (2021) 11 (1), 24444 DOI: 10.1038/s41598-021-04007-y
Cited by 16
AI Summary: OriGene’s Breast Cancer cDNA array IV (BCRT104) was used in this study to analyze HNRNPA1 mRNA isoform expression in breast cancer samples, facilitating the identification of a cancer-specific isoform switch.
Snippet: solation, cDNA synthesis and RT-qPCR were performed as described16,17 (Supplementary Table S1). RPLP0 was used as reference gene for RT-qPRs. Breast cancer cell lines and Breast Cancer cDNA array IV (Origene, BCRT104) were used as described16,17. Rapid amplification of cDNA ends (RACE)-specific cDNA synthesis was performed using the 3′ RACE Kit (Roche). Cells were treated with actinomycin D (Toc
FigureFigureFigure
INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer
Rodgers, Ooms, Oorschot et al
Nat Commun (2021) 12 (1), 3140 DOI: 10.1038/s41467-021-23241-6
Cited by 66
AI Summary: OriGene’s Tissue Scan Breast Cancer cDNA arrays I-IV (BCRT101, BCRT102, BCRT103, and BCRT104) were used to measure INPP4B mRNA expression in primary human breast cancer and normal tissues, contributing essential data for the study's analysis of INPP4B expression patterns.
Snippet: 1b, c). As mRNA expression data were not available for these cohorts, INPP4B mRNA expression was examined using Tissue Scan Breast Cancer cDNA arrays I-IV (OriGene) of 130 primary human breast cancers and 16 normal breast tissues (Fig. 1c);Breast cancer cDNA arrays (176 breast cancers and 16 tumor adjacent normal breast tissues) were purchased from OriGene (BCRT101, BCRT102, BCRT103, and BCRT104)
PtdIns(3,4,5)P3-dependent Rac exchanger 1 (P-Rex1) promotes mammary tumor initiation and metastasis
Srijakotre, Liu, Nobis et al
Proc Natl Acad Sci U S A (2020)
Cited by 20
AI Summary: OriGene’s TissueScan Human Breast Cancer cDNA arrays I–IV were used to measure PREX1 mRNA expression in normal and breast cancer tissue samples, enabling the authors to correlate PREX1 levels with clinical outcomes in breast cancer.
Snippet: To this end we examined PREX1 mRNA expression in TissueScan Human Breast Cancer cDNA arrays I–IV (OriGene), which contain 16 “normal” breast tissues and 176 primary breast cancer samples
The long non-coding RNA GHSROS facilitates breast cancer cell migration and orthotopic xenograft tumour growth
Thomas, Seim, Jeffery et al
Int. J. Oncol. (2019)
AI Summary: OriGene's TissueScan Cancer Survey Tissue qPCR panels (BCRT101, BCRT102, BCRT103, and BCRT104) were used in this study to analyze GHSROS expression levels in breast tissue samples, enabling the comparison between breast tumor and normal tissues.
Snippet: breast tissue samples. Briefly, TissueScan Cancer Survey Tissue qPCR panels BCRT101, BCRT102, BCRT103 and BCRT104 were arrayed onto a single 384‑well reaction plate by OriGene Technologies, Inc. Data are expressed
Divergent effects of vitamins K1 and K2 on triple negative breast cancer cells
Beaudin, Kokabee, Welsh
Oncotarget (2019) 10 (23), 2292-2305 DOI: 10.18632/oncotarget.26765
Snippet: TissueScan Disease Tissue qPCR Arrays (#BCRT104, Origene) were used to assess gene expression in 48 samples (4-normal, 2-Stage IA, 15-Stage IIA, 9-Stage IIB, 7-Stage IIIA, 4-Stage IIIB, 6-Stage IIIC, 1-Stage IV). Data was normalized to β-Actin expression and expressed relative to values obtained from normal tissue (N). Bars represent mean ± SEM. (D) GGCX protein expression in human breast tumors
FigureFigureFigure
Showing 1-6 of 20 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Related Products